Role of Cyclooxygenase-1 and -2, Phospholipase C, and Protein Kinase C in Prostaglandin-Mediated Gastroprotection
Authors:
- Brigitta M. PeskarBPBrigitta M. Peskar
- Nadia SawkaNSNadia Sawka
- Karlheinz EhrlichKEKarlheinz Ehrlich
- Bernhard A. PeskarBPBernhard A. Peskar
- 1 June 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (3) , 1233-1238
Abstract
Oral administration of the nonselective cyclooxygenase (COX) inhibitor indomethacin (20 mg/kg), the COX-1 inhibitor 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560) (20 mg/kg), or the COX-2 inhibitor rofecoxib (1–20 mg/kg) antagonized the gastroprotective effects of 16,16-dimethyl-prostaglandin (PG) E2 (75 ng/kg p.o.) and 20% ethanol in rats. The effects of the COX inhibitors were reversed by the activator of ATP-sensitive potassium (KATP) channels cromakalim (0.3–0.5 mg/kg p.o.). The protective effects of 16,16-dimethyl-PGE2 and 20% ethanol were counteracted by the phospholipase C inhibitor 1-(6-((17β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U-73122), but not its inactive analog 1-(6-((17β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-2,5-pyrrolidine-dione (U-73343) (1 mg/kg each i.v.). Likewise, the protein kinase C inhibitors chelerythrine (0.7 mg/kg i.v.) and staurosporine (3 μg/kg i.v.) inhibited gastroprotection. Effects of these enzyme inhibitors were not reversed by cromakalim. Submaximally effective doses of SC-560 (0.2 mg/kg p.o.) and rofecoxib (0.02 mg/kg p.o.) were additive and abolished the protection induced by 20% ethanol. The findings show that inhibition of COX-1 or COX-2 antagonizes not only adaptive gastroprotection by 20% ethanol but also the protective effect of exogenous PG in a cromakalimsensitive manner. Endogenous PG obviously add to the protective activity of exogenous PG. Gastroprotection by PG involves phospholipase C, protein kinase C, and KATP channels. Activation of KATP channels does not exert protection when the activity of phospholipase C or protein kinase C is suppressed.Keywords
This publication has 26 references indexed in Scilit:
- Effects of specific inhibition of cyclo‐oxygenase‐1 and cyclo‐oxygenase‐2 in the rat stomach with normal mucosa and after acid challengeBritish Journal of Pharmacology, 2001
- Selective activation of E-type prostanoid3-receptors reduces myocardial infarct sizePharmacology & Therapeutics, 2000
- Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injuryEuropean Journal of Pharmacology, 1999
- Reduction of myocardial injury by the EP3 receptor agonist TEI-3356. Role of protein kinase C and of KATP-channelsEuropean Journal of Pharmacology, 1999
- Selective cyclo‐oxygenase‐2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomachBritish Journal of Pharmacology, 1998
- Protein kinase C. Its role in ischemic preconditioning in the rat.Circulation Research, 1994
- Prostaglandin protects isolated guinea pig chief cells against ethanol injury via an increase in diacylglycerol.Journal of Clinical Investigation, 1990
- Chelerythrine is a potent and specific inhibitor of protein kinase CBiochemical and Biophysical Research Communications, 1990
- Hyperpolarizing Vasodilators Activate ATP-sensitive K + Channels in Arterial Smooth MuscleScience, 1989
- Effect of 16,16 dimethyl prostaglandin E2 on aspirin induced damage to rat gastric epithelial cells in tissue culture.Gut, 1984